Key contacts

Dean Richardson
Director, Australasia

Regional office - Australia
Level 12, office 1205
95 Pitt Street
Sydney
NSW 2000
Australia
Tel: +61 (0)2 8249 8342

Regional office - New Zealand
Edison Investment Research (NZ) Ltd
PO Box 10293
Te Rapa
Hamilton
3241
Tel: +61 (0)2 8249 8342

listed companies

Range Resources Nkwe Platinum
MEC Resources Coal of Africa
Syndicated Metals Gold One
Bionomics Allied Gold Mining
Phylogica ADX Energy
Alkane Resources Bellzone Mining
Sumatra Copper & Gold Continental Coal
Gunson Resources RedFlow
Lochard Energy Circadian Technologies
Universal Coal Biotron
See more

Companies with HQs in asia-pacific

Seeing Machines Forterra Trust
Greka Drilling Bezant Resources
Green Dragon Gas Baobab Resources
Endace Wynnstay Group
PXP Vietnam Fund Chatham Rock Phosphate
Tenon MMG
SeaDragon Contact Energy
Snakk Media Cue Energy
New Zealand Oil & Gas Rubicon
Sky Network Television Sealegs Corporation
See more

Latest research

Pacific Edge

Anticipating commercial growth

Outlook | Pharmaceutical & healthcare | 09/01/2018

Pacific Edge continues to make progress commercialising its suite of bladder cancer diagnostics products, with three tests currently available in the US market. An uplift in sales is expected as TRICARE and the Veterans Administration (VA) are under contract, although the exact timing of a sales ramp is unknown. In addition, the company’s discussions with Kaiser Permanente are nearing a final decision and progress has been made with achieving inclusion in the local coverage determination (LCD)…

Kazia Therapeutics

GDC-0084 Phase II to begin shortly

ADR Update | Pharmaceutical & healthcare | 21/12/2017

Novogen has changed its name to Kazia Therapeutics and undertaken a 10:1 share consolidation following shareholder approval in November. It has also out-licensed its preclinical super-benzopyran development program, and has added a dose optimization lead-in component to the Phase II trial of GDC-0084 in glioblastoma, which is expected to commence in early 2018. Although the more focused pipeline and longer Phase II trial for GDC-0084 prompts us to trim our valuation to between $53m and $96m, we believe…

Kazia Therapeutics

GDC-0084 Phase II to begin shortly

Update | Pharmaceutical & healthcare | 21/12/2017

Novogen has changed its name to Kazia Therapeutics and undertaken a 10:1 share consolidation following shareholder approval in November. It has also out-licensed its preclinical super-benzopyran development programme, and has added a dose optimisation lead-in component to the Phase II trial of GDC-0084 in glioblastoma, which is expected to commence in early 2018. Although the more focused pipeline and longer Phase II trial for GDC-0084 prompts us to trim our valuation to between A$69m and A$127m,…

Bionomics

A novel method of treating anxiety disorders

QuickView | Pharmaceutical & healthcare | 18/12/2017

Bionomics’ lead programme is BNC210 for the treatment of anxiety-related disorders. The drug is an orally bioavailable small molecule targeting the α7 nicotinic acetylcholine receptor, which has been implicated in the brain’s response to anxiety. It is currently being tested in a randomized, double-blind Phase IIb clinical study of 192 post-traumatic stress disorder (PTSD) patients, with top-line results expected in H218.

SymBio Pharmaceuticals

Licence agreement for IONSYS terminated

ADR Update | Pharmaceutical & healthcare | 15/12/2017

The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in Japan has terminated effective 30 November. SymBio is seeking damages of at least $82m (¥9bn) arising from MDCO’s repudiation of the licence agreement. The termination is in line with our expectations after MDCO voluntarily withdrew IONSYS from sale in the US market in June; any compensation payments received from MDCO would represent upside to…

About

Edison‘s Sydney and Wellington offices opened in 2011 to provide research services to companies listed on Asia-Pacific stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of research and unrivalled distribution of our reports on a global and unrestricted basis.

Sector Commentary

See more reports See more reports See more reports

Sector Reports

See more sector reports See more sector reports See more sector reports